Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

ABSTRACT:

Background

The PlanB registry evaluated long-term follow-up data for clinical candidates for chemotherapy enrolled in the PlanB trial in hormone receptor (HR)-positive early breast cancer (eBC) patients preselected using the 21-gene expression assay.

Patients and methods

PlanB randomly assigned pT1-4c, pN+, pN0/high-risk human epidermal growth factor receptor 2 (HER2)-negative eBC patients to four cycles of epirubicin + cyclophoshamide followed by four cycles of docetaxel (EC-T arm) or to six cycles of docetaxel + cyclophosphamide (TC); patients with locally HR-positive tumors and recurrence score (RS) <12 received endocrine therapy (ET) only. Following the end of PlanB, patients with HR-positive tumors were included in a prospective, noninterventional PlanB registry. The pr

SUBMITTER: Nitz U 

PROVIDER: S-EPMC12702365 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature